

Over the last decade, we closely covered the Sovaldi® (sofosbuvir) patent battles here. And Merck's intitial multi-billion dollar verdict has been closed out, as the Supremes declined the case to re-instate that verdict, after an appeals court ruled Merck's patents invalid. Here's the bit, from FiercePharma, yesterday:
. . .In its Tuesday update, the Supreme Court said it would not take up the lawsuit between Merck subsidiary Idenix Pharmaceuticals and Gilead Sciences. Merck had won the $2.54 billion patent verdict in 2016 when a jury found Gilead had infringed on a Merck patent. The jury ordered Gilead to shell out those billions because of its high sales for hep C meds Harvoni and Sovaldi.
During the years that followed, the companies battled over the massive award. In 2018, a federal judge found Merck’s ‘597 patent invalid and overturned the verdict. . . .
Onward, with three new inches, soft and fluffy on the ground -- and a bright, single digits windchilled day out there -- Lady Gaga and J.Lo killed it! Huge grins, henceforth. . . .
नमस्ते
No comments:
Post a Comment